US Bancorp DE Sells 530 Shares of DaVita Inc. (NYSE:DVA)

US Bancorp DE reduced its stake in shares of DaVita Inc. (NYSE:DVA) by 17.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,443 shares of the company’s stock after selling 530 shares during the quarter. US Bancorp DE’s holdings in DaVita were worth $374,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. UMB Bank n.a. grew its stake in shares of DaVita by 65.5% during the first quarter. UMB Bank n.a. now owns 192 shares of the company’s stock valued at $29,000 after purchasing an additional 76 shares during the last quarter. Copia Wealth Management bought a new stake in shares of DaVita during the fourth quarter valued at approximately $30,000. Coppell Advisory Solutions LLC grew its stake in shares of DaVita by 50.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company’s stock valued at $45,000 after purchasing an additional 100 shares during the last quarter. Canada Post Corp Registered Pension Plan bought a new stake in shares of DaVita during the fourth quarter valued at approximately $55,000. Finally, GeoWealth Management LLC boosted its stake in DaVita by 30.6% in the fourth quarter. GeoWealth Management LLC now owns 525 shares of the company’s stock valued at $79,000 after acquiring an additional 123 shares during the last quarter. 90.12% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on DVA shares. Wall Street Zen raised shares of DaVita from a “hold” rating to a “buy” rating in a research note on Friday, April 25th. Barclays reduced their price objective on shares of DaVita from $169.00 to $160.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 7th. Finally, Truist Financial set a $148.00 price objective on shares of DaVita in a research note on Friday, August 8th.

Insider Buying and Selling at DaVita

In other news, insider James O. Hearty sold 2,351 shares of DaVita stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total transaction of $352,650.00. Following the transaction, the insider directly owned 26,038 shares of the company’s stock, valued at $3,905,700. This trade represents a 8.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.50% of the stock is currently owned by corporate insiders.

DaVita Price Performance

Shares of DVA stock opened at $134.60 on Thursday. DaVita Inc. has a 52-week low of $126.07 and a 52-week high of $179.60. The stock has a market cap of $9.62 billion, a PE ratio of 13.24, a PEG ratio of 0.95 and a beta of 1.09. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.34 and a current ratio of 1.39. The firm’s 50 day moving average price is $139.80 and its two-hundred day moving average price is $146.02.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share for the quarter, topping analysts’ consensus estimates of $2.70 by $0.25. The company had revenue of $3.38 billion for the quarter, compared to analysts’ expectations of $3.36 billion. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The business’s quarterly revenue was up 6.1% compared to the same quarter last year. During the same period last year, the firm posted $2.00 earnings per share. As a group, analysts forecast that DaVita Inc. will post 10.76 EPS for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.